What is HC Wainwright's Estimate for Celcuity Q1 Earnings?

Celcuity Inc. (NASDAQ:CELC - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Celcuity in a report issued on Monday, May 19th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($1.09) for the quarter. HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's Q2 2026 earnings at ($1.13) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($0.71) EPS, FY2028 earnings at $1.26 EPS and FY2029 earnings at $3.26 EPS.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09.

Separately, Needham & Company LLC reissued a "buy" rating and issued a $29.00 target price on shares of Celcuity in a research report on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $30.80.

Celcuity Stock Performance

Shares of NASDAQ:CELC traded down $0.31 during mid-day trading on Tuesday, reaching $10.44. The company had a trading volume of 144,757 shares, compared to its average volume of 299,449. Celcuity has a one year low of $7.58 and a one year high of $19.77. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company's 50-day moving average price is $10.19 and its 200-day moving average price is $11.50. The firm has a market cap of $395.32 million, a price-to-earnings ratio of -4.00 and a beta of 0.56.

Institutional Trading of Celcuity

Several hedge funds and other institutional investors have recently modified their holdings of CELC. Summit Investment Advisors Inc. lifted its holdings in shares of Celcuity by 49.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after buying an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in Celcuity during the fourth quarter valued at approximately $50,000. Focus Financial Network Inc. bought a new stake in Celcuity during the 1st quarter worth approximately $108,000. Perkins Capital Management Inc. purchased a new stake in Celcuity in the 1st quarter worth approximately $115,000. Finally, GAMMA Investing LLC lifted its stake in Celcuity by 1,237.4% in the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after purchasing an additional 1,225 shares in the last quarter. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.